WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

• 

• Emily C. de los Reyes, MD

  Pediatric Neurologist
  Nationwide Children’s Hospital
  Professor of Clinical Pediatrics and Neurology
  The Ohio State University College of Medicine
  Columbus, Ohio

  Disclosures

  Emily C. de los Reyes, MD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Amicus; BioMarin Pharmaceutical Inc.; Zogenix
  Served as a speaker or a member of a speakers bureau for: Amicus; BioMarin Pharmaceutical Inc.
  Received grants for clinical research from: Amicus; BioMarin Pharmaceutical Inc.
  Contracted researcher for: Amicus; BioMarin
  Royalties: Amicus

• 

• Miriam Nickel, MD

  Department of Pediatrics
  University Medical Center Hamburg-Eppendorf
  Hamburg, Germany

  Disclosures

  Miriam Nickel, MD, has no relevant financial relationships.

• 

• Angela Schulz, MD, PhD

  Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  Disclosures

  Angela Schulz, MD, PhD, has disclosed the following relevant financial relationships:
  Served as an advisor or consultant for: Amicus; BioMarin; Neurogene; RegenxBio; Taysha

• 

• Nicola Specchio, MD, PhD

  Department of Neurosciences, Neurology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

  Disclosures

  Nicola Specchio, MD, PhD, has disclosed no relevant financial relationships.

• 

• Raymond Wang, MD

  Campbell Foundation Director
  Multidisciplinary Lysosomal Disorder Program
  Children's Hospital of Orange County
  Orange, California, United States

  Disclosures

  Raymond Wang, MD, has the following relevant financial relationships:
  Served as an advisor or consultant for: BioMarin; Denali; Inventiva; M6P Therapeutics; Orphazyme; Sio Gene Therapies; RegenxBio; Takeda
  Received grants for clinical research from: BioMarin Pharmaceuticals; Ultragenyx
  Stock options from: M6P Therapeutics
  Owns stock (privately owned) in: M6P Therapeutics
  Owns stock (publicly traded) in: BioMarin; RegenxBio

Editor

• Rita Moreira da Silva, PhD, MA, PharmD

  Medical Education Director, WebMD Global, LLC

  Disclosures

  Rita Moreira da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

• Susan L. Smith, MN, PhD

  Associate Director, Accreditation and Compliance

  Disclosures

  Susan L. Smith, MN, PhD, has no relevant financial relationships.